Relevance and necessity of studies on second-line chemotherapy in melanoma

Onkologie

Volumn 27, Issue 6, 2004, Pages 527-528

  Agarwala, Sanjiv S ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; INTERLEUKIN 12; OBLIMERSEN;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG APPROVAL; EDITORIAL; HUMAN; MELANOMA; MONOTHERAPY; NONHUMAN;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DACARBAZINE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; INTERLEUKIN-2; MELANOMA; PHYSICIAN'S PRACTICE PATTERNS; TREATMENT OUTCOME;

EID: 10844250049     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082121     Document Type: Editorial

References (12)

1. Millward MJ, Bedikian AY, Conry RM et al.: Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): Analysis of long-term survival. Am Soc Clin Oncol 2004;23:708.
2. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saiag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y: Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. J Clin Oncol 2004;22:1118-1125.
3. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-2116.
4. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745-2751.
5. Agarwala SS, Ferri W, Gooding W, Kirkwood JM: A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer 1999;85:1979-1984.
6. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH: Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 1998;16:1743-1751.
7. Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HKB, Verma S, Armitage GR, Zee B, Bennett K: Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 1996;14:2083-2090.
8. Atkins M, Lee S, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM: A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial. Proc Am Soc Clinc Oncol 2003:708.
9. Keilholz U, Punt CJ, Gore M, Suciu S, Kruit W, Patel P, Lienard D, Thomas J, Lehman F, Eggermont AM: Dacarbazine, cisplatin and IFN-a2b with or without IL-2 in advanced melanoma: Final analysis of EORTC randomized phase III trial 18951. Proc Am Soc Clin Oncol 2003:708.
10. Del Vecchio M, Bajetta E, Vitali M, Gattinoni L, Santinami M, Daponte A, Sertoli MR, Queirolo P, Bernengo MG, Cascinelli N: Multicenter phase III randomized trial of cisplatin, vindesine and dacarbazine (CVD) versus CVD plus subcutaneous (sc) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma patients (pts). Proc Am Soc Clin Oncol 2003:709.
11. Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, Gonzalez R, Hersh E, Feun L, Belt R, Meyskens F, Hellstrand K, Wood D, Kirkwood JM, Gehlsen KR, Naredi P: Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002;20:125-133.
12. Fink W, Zimpfer-Rechner C, Thoelke A, Figl R, Kaatz M, Ugurel S, Schadendorf D: Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma. Onkologie 2004;27:540-544.